Search for: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
Results 41 - 60
of 233
Sort by Relevance
|
Sort by Date
9 Jan 2017, 9:36 am
In other words, Copaxone should remain a $4 billion drug, annually.link to Pantagraph: http://www.pantagraph.com/business/investment/markets-and-stocks/factors-that-sent-teva-pharmaceutical-industries-ltd-sliding-in/article_74234eee-a5ec-5c58-a54b-82597151b1e6.htmlPatents covering "three per week" dosing were not at issue in the Supreme Court case of Teva Pharmaceuticals USA, Inc. v. [read post]
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
28 Dec 2016, 10:06 am
On December 22, 2016, Teva Pharmaceutical Industries Ltd. [read post]
27 Dec 2016, 2:50 pm
The world’s largest manufacturer of generic pharmaceuticals, Israeli-based Teva Pharmaceutical Industries Ltd. [read post]
14 Nov 2016, 9:16 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
8 Nov 2016, 11:53 pm
Next, on November 6, 2016, plaintiffs’ lawyers’ filed a securities class action lawsuit in the Central District of California against Teva Pharmaceuticals Industries Ltd. [read post]
13 Oct 2016, 6:50 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
28 Sep 2016, 8:39 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
18 Sep 2016, 6:03 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
2 Sep 2016, 1:57 pm
There, plaintiffs brought a putative class action complaint challenging the sale of Auspex Pharmaceuticals, Inc. to Teva Pharmaceuticals Industries, Inc. [read post]
25 Aug 2016, 2:11 pm
Finance.yahoo noted a PTAB ruling on some of Teva's Copaxone patents:Teva Pharmaceutical Industries Ltd. today [August 24, 2016] confirmed the Patent Trial and Appeal Board (PTAB) decisions from an Inter Partes Review (IPR) to invalidate all claims of the ‘250 and ‘413 patents for 40 mg COPAXONE® (glatiramer acetate injection). [read post]
17 Mar 2016, 12:12 pm
The allegations of infringement have been directed at Defendants Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania and its parent company Teva Pharmaceutical Industries Ltd. of Israel. [read post]
1 Dec 2015, 6:20 am
”) to ward off an unsolicited takeover bid by the Israeli pharmaceutical company Teva Pharmaceutical Industries Ltd. [read post]
7 Sep 2015, 1:02 pm
Pointing to a number of shortcomings in patents in agriculture and pharmaceuticals, The Economist concludes that patents don’t. [read post]
26 Aug 2015, 11:02 am
., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. [read post]
26 Jun 2015, 7:44 am
Law360.com provides insight into the background of the dispute in an article (subscription required for full access) that begins, "Drug purchasers challenging a no-authorized-generic settlement between GlaxoSmithKline PLC and Teva Pharmaceutical Industries ltd. told the Third Circuit on Friday that the U.S. [read post]
16 Jun 2015, 6:00 am
Teva Pharmaceutical Industries, Ltd. will make a total of $1.2B available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon’s illegal conduct. [read post]
4 Jun 2015, 8:00 am
Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd. in 2011. [read post]
25 May 2015, 4:15 am
The parties have been back in court to fight over other patents, resulting in the decision Synthon B.V. v Teva Pharmaceutical Industries Ltd [2015] EWHC 1395 (Pat), which came out last week and which Darren reports in timely fashion.* When functionality cuts deep, it can be hard to handle: Yoshida appeal dismissedValentina's back again to pen on General Court's decision in Joined Cases C‑337/12 P to… [read post]
21 May 2015, 10:39 am
The parties have been back in court to fight over other patents, resulting in the decision Synthon B.V. v Teva Pharmaceutical Industries Ltd [2015] EWHC 1395 (Pat), which came out this morning.The patents concerned are EP (UK) 2 177 528 and EP (UK) 2 361 924, both divisionals of EP (UK) 1 799 703, which was revoked by the EPO in opposition proceedings pursuant to Teva's withdrawal of it after a negative preliminary opinion. [read post]
